Similar articles

• [The cost-effectiveness of hormonal replacement therapy].

  Ylikorkala O. Ylikorkala O. Duodecim. 1996;112(12):1039-40. Duodecim. 1996. PMID: 10593003 Finnish. No abstract available.
• [The role of progestin in menopausal hormonal replacement therapy].

  Kauppila A. Kauppila A. Duodecim. 1996;112(12):1097-103. Duodecim. 1996. PMID: 10593011 Review. Finnish. No abstract available.
• The effects of transdermal and oral estrogen/progesterone regimens on free and total protein S in postmenopausal women.

  Marque V, Alhenc-Gelas M, Plu-Bureau G, Oger E, Scarabin PY. Marque V, et al. Thromb Haemost. 2001 Aug;86(2):713-4. Thromb Haemost. 2001. PMID: 11522028 No abstract available.
• [Hormone therapy and risk of venous thromboembolism: new insights from the ESTHER study].

  Canonico M, Scarabin PY. Canonico M, et al. Med Sci (Paris). 2008 Mar;24(3):228-31. doi: 10.1051/medsci/2008243228. Med Sci (Paris). 2008. PMID: 18334161 French. No abstract available.
• Current trends in hormone replacement therapy.

  Khashoggi TY. Khashoggi TY. Saudi Med J. 2002 May;23(5):495-502. Saudi Med J. 2002. PMID: 12070567 Review.